DeGolyer Donald W's Form 4 filing
Emergent BioSolutions Inc.EBS · filed Nov 14, 2024
- Accession no.
- 0001367644-24-000186
- Filed
- Nov 14, 2024
- Trade date
- Nov 12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $272.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| DeGolyer Donald WCIK 0001583098 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Common Stock | SSaleDisposed | −25,000 | $10.91F1 | −$272,750 | 111,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On November 12, 2024, Mr. DeGolyer sold an aggregate of 25,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.83 - $11.05. The Company maintains a record of the transactions and copies will be provided upon request.
Referenced by the price of 1 transaction in Table I.